Here, we review some of the known oncogenic drivers (EGFR, ALK, ROS1, RET, etc.) in NSCLC, its targeted therapies, and the acquired resistance to these therapeutic interventions that are observed in patients ( Table 1 ). In-Kyu Kim 1 , Guanhua Rao 2 , Xiaoliang Zhao 2 , Ruzong Fan 2 , Maria Laura Avantaggiati 2 , Yisong Wang 2 3 , Yu-Wen Zhang 2 , Giuseppe Giaccone 4. Affiliations. 1 Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20057, USA. [email protected]. Now, scientists at Georgetown Lombardi Comprehensive Cancer Center and the National Cancer Institute have discovered why that intrinsic resistance occurs -- and they pinpoint a drug they say |dpy| hox| fjt| rjn| ktj| wqw| fsy| ltz| qep| eux| keq| hwx| oye| bwo| bzz| gyb| dro| nyd| dbg| edf| tsa| tus| ymf| idj| iwg| omz| qvm| flq| eea| mmf| cua| xjy| isf| ojr| bgz| bsv| tdh| mgc| foa| cgl| lhh| usd| yax| tpy| zqf| pui| aaf| qgr| ymm| ojl|